|
Wednesday, March 2, 2022 |
|
Avance Clinical Announces New Office Opening in Sydney |
Avance Clinical, the largest premium Australian Contract Research Organisation (CRO) for international biotechs, has opened new offices in Sydney to support its growing clinical team in the greater Sydney region. more info >> |
|
Avance Clinical悉尼办公室正式启动 |
Avance Clinical是澳大利亚本地最大的CRO,致力于协助世界各地的生物科技以及制药公司完成早期临床研究。目前,我们的悉尼办公室已经正式启动,以协助大悉尼地区日益壮大的临床运营团队。 more info >> |
|
Avance Clinical悉尼辦公室正式啟動 |
Avance Clinical是澳大利亞本地最大的CRO,致力於協助世界各地的生物科技以及製藥公司完成早期臨床研究。目前,我們的悉尼辦公室已經正式啟動,以協助大悉尼地區日益壯大的臨床運營團隊。 more info >> |
|
Wednesday, January 19, 2022 |
|
Avance Clinical在2022年生物技術展上宣佈為美國擴張進行重大私募股權投資 |
Avance Clinical 是澳大利亞最大的國際生物技術高級合同研究組織 (CRO),已獲得全球私募股權公司 Riverside Company (Riverside) 的重大投資,以支持進一步的區域和全球擴張。該投資對公司的估值超過 2 億美元。 more info >> |
|
아방스 클리니컬 바이오테크 쇼케이스 2022에서 미국에서의 확장을 위한 대규모적인 PE 투자를 발표 |
글로벌 바이오테크 시장의 가장 큰 프리미엄 호주 임상수탁기관(CRO)인 아방스 클리니컬은 글로벌 사모펀드 회사인 리버사이드(Riverside)사로부터 앞으로의 지역 및 글로벌 확장을 위한 상당한 투자를 확보하였다. 투자로 하여 회사의 가치는 2억 달러를 넘어섰다. more info >> |
|
Avance Clinical在2022年生物技术展上宣布为美国扩张进行重大私募股权投资 |
Avance Clinical 是澳大利亚最大的国际生物技术高级合同研究组织 (CRO),已获得全球私募股权公司 Riverside Company (Riverside) 的重大投资,以支持进一步的区域和全球扩张。 该投资对公司的估值超过 2 亿美元。 more info >> |
|
Tuesday, January 18, 2022 |
|
Avance Clinical Announces Major PE Investment for US Expansion at Biotech Showcase 2022 |
Avance Clinical, the largest premium Australian Contract Research Organisation (CRO) for international biotechs, has secured a significant investment from global private equity firm, The Riverside Company (Riverside), to support further regional and global expansion. The investment values the company in excess of $200m. more info >> |
|
Tuesday, October 19, 2021 |
|
Avance Clinical Client News: XWPharma Initiates First-in-Human Studies of XW10508, in Development for Fast-acting Relief of Treatment-Resistant Depression and Chronic Pain |
Avance Clinical, the largest premium Australian CRO for international biotechs, is pleased to share the news that its client XWPharma Ltd. has announced dosing of subjects in its first-in-human study evaluating XW10508, the Company's novel, patented, glutamatergic NMDA antagonist and AMPA activator in development as an oral, once-daily therapy for the treatment of treatment-resistant depression and chronic pain. more info >> |
|
Avance Clinical临床试验合作申办方XWPharma正式开启其XW10508首次人类临床试验,研究快速缓解难治性抑郁症以及慢性疼痛疗法 |
Avance Clinical的临床试验合作申办方XWPharma正式宣布其XW10508首次人类临床试验进入给药阶段。XW10508是一种谷氨酸能NMDA抑制剂和AMPA激活剂,作为一种治疗难治性抑郁症以及慢性疼痛的创新型口服药物,其给药剂量为每日一次。XWPharma已经为其注册专利。 more info >> |
|
Avance Clinical臨床試驗合作申辦方XWPharma正式開啟其XW10508首次人類臨床試驗,研究快速緩解難治性抑鬱症以及慢性疼痛療法 |
Avance Clinical的臨床試驗合作申辦方XWPharma正式宣布其XW10508首次人類臨床試驗進入給藥階段。 XW10508是一種穀氨酸能NMDA抑製劑和AMPA激活劑,作為一種治療難治性抑鬱症以及慢性疼痛的創新型口服藥物,其給藥劑量為每日一次。 XWPharma已經為其註冊專利。 more info >> |
|
|
|